TY - JOUR
TI - Generalized bullous fixed drug eruption to fluconazole with positive patch testing and confirmed tolerance to itraconazole
AU - Makris, M.
AU - Fokoloros, C.
AU - Syrmali, A.
AU - Tsakiraki, Z.
AU - Damaskou, V.
AU - Papadavid, E.
JO - Iranian Journal of Allergy, Asthma and Immunology
PY - 2021
VL - 20
TODO - 2
SP - 255-258
PB - Tehran University of Medical Sciences
SN - null
TODO - 10.18502/ijaai.v20i2.6081
TODO - 2 phenoxyethanol;  C reactive protein;  emollient agent;  fluconazole;  itraconazole;  ketoconazole;  octenidine;  prednisolone;  antifungal agent;  fluconazole;  itraconazole, aged;  Article;  burning sensation;  case report;  clinical article;  cream;  cross reaction;  diagnostic procedure;  drug analysis;  drug dose reduction;  drug synthesis;  drug tolerance;  drug volume;  drug weight;  fixed drug eruption;  generalized bullous fixed drug eruption;  human;  human tissue;  hyperpigmentation;  male;  oral mucosal disease;  patch test;  provocation test;  pruritus;  skin biopsy;  skin defect;  thrush;  drug eruption;  drug tolerance;  patch test, Aged;  Antifungal Agents;  Candidiasis, Oral;  Drug Eruptions;  Drug Tolerance;  Fluconazole;  Humans;  Itraconazole;  Male;  Patch Tests
TODO - Generalized bullous fixed drug eruption (GBFDE) is a specific variant of fixed drug eruption that belongs to severe cutaneous adverse reactions (SCARs) and its diagnosis is based mainly on clinical course and especially on the reoccurrence of typical bullous lesions in previous and new sites after re-administration of the offending drug. We present a well-documented case of fluconazole-induced GBFDE, with a positive patch test to fluconazole (30% weight/volume preparation) and clinical tolerance to itraconazole proven by negative oral provocation. Even in SCARs, patch testing represents a useful diagnostic tool, while oral provocation remains the gold standard in cases that an alternative but the chemically relevant drug must be administered. Copyright © 2021 Makris et al.
ER -